IMPACT OF PHARMACEUTICAL CARE ON OPTIMIZING STATIN AND ANTICOAGULANT USE IN PATIENTS WITH INCREASED CARDIOVASCULAR RISK

Abstract

This study analyzes the impact of pharmaceutical care on optimizing statin and anticoagulant therapy in patients with increased cardiovascular risk. Cardiovascular diseases represent the leading cause of global mortality, requiring complex and combined therapeutic interventions. Although the association of HMG-CoA reductase inhibitors and anticoagulant agents has a solid clinical rationale for preventing ischemic and thromboembolic events, their concomitant use significantly elevates the risk of pharmacokinetic (CYP450 pathways) and pharmacodynamic drug-drug interactions, predisposing patients to myalgia, muscle toxicity, and severe hemorrhages. Given this high-vulnerability scenario, especially in elderly and polymedicated individuals, pharmaceutical care acts as an indispensable safety barrier. Targeted clinical interventions, materialized through continuous pharmacotherapeutic follow-up, medication reconciliation, active monitoring of laboratory parameters, and adherence-focused educational support, demonstrate efficacy in mitigating drug-related problems. It is concluded that the systematic integration of the pharmacist into the multidisciplinary team optimizes clinical outcomes, reduces hospital readmission rates, and ensures the essential rationality and safety required for highly complex cardiovascular treatment.